Rallybio Corp

Name: Rallybio Corp standardized financial statements, quarterly
Creator: Listed

RLYBNasdaqCIK 1739410HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$0, Q3 FY2026

Operating income−$3.4m, Q3 FY2026

Net income−$2.7m, Q3 FY2026

Rallybio Corp, income statement, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Revenue	$m	not reported	0.0	0.3	0.3	0.0	0.2	0.2	0.2	0.2	0.2	0.0	0.0
Research and development	$m	15.9	12.9	12.9	8.2	7.4	5.7	6.1	4.1	3.7	2.9	0.8	0.6
Operating income	$m	(21.1)	(19.8)	(17.0)	(12.1)	(11.6)	(9.7)	(10.1)	(6.9)	(6.4)	(8.7)	(5.7)	(3.4)
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	not reported	not reported	not reported	not reported	not reported	not reported	0.0	0.0	0.0	not reported	1.3	0.1
Net income	$m	(20.2)	(19.0)	(16.2)	(11.5)	(11.0)	(9.4)	(9.7)	16.0	(5.9)	(8.3)	43.7	(2.7)
Diluted EPS	$ per share	not reported	(0.47)	(0.37)	(0.26)	not reported	(1.69)	(0.22)	2.84	not reported	(1.46)	7.53	(0.48)
Basic EPS	$ per share	not reported	(0.47)	(0.37)	(0.26)	not reported	(1.69)	(1.73)	2.84	not reported	(1.46)	7.66	(0.48)

Balance sheet

Cash and equivalents$90.7m, Q3 FY2026

Shareholders' equity$92.3m, Q3 FY2026

Rallybio Corp, balance sheet, quarterly
Line item	Unit	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Cash and equivalents	$m	24.5	19.3	16.7	25.3	13.9	14.8	9.4	32.1	31.4	41.3	92.8	90.7
Current assets	$m	115	98.5	91.4	78.2	67.8	57.4	50.3	66.6	61.3	53.5	97.3	94.8
Total assets	$m	116	99.4	92.4	79.0	68.1	58.0	51.0	67.7	62.3	54.5	98.1	95.6
Current liabilities	$m	9.3	10.1	12.2	8.2	6.2	3.9	5.0	4.5	4.2	4.1	3.6	3.3
Total liabilities	$m	9.4	10.2	12.4	8.2	6.5	3.9	5.0	4.6	4.3	4.2	3.6	3.3
Shareholders' equity	$m	106	89.2	80.0	70.8	61.7	54.1	46.0	63.0	58.0	50.3	94.5	92.3

Cash flow

Operating cash flow−$2.3m, Q3 FY2026

Capital expenditure$12.0k, Q4 FY2023

Rallybio Corp, cash flow, quarterly
Line item	Unit	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Operating cash flow	$m	(11.6)	(15.5)	(10.4)	(13.5)	(9.9)	(10.2)	(8.4)	(6.6)	(4.7)	(8.0)	45.9	(2.3)
Capital expenditure	$m	0.0	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)5.72m, Q3 FY2026

Rallybio Corp, shares, quarterly
Line item	Unit	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30	Q3 FY20262026-09-30
Diluted shares (weighted)	m shares	40.2	40.4	40.5	40.8	44.1	44.6	5.6	44.8	5.6	5.7	5.8	5.7

Shares outstanding: 5.38m at Oct 20, 2026, from the cover of the 10-Q filed Oct 27, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:38 ET. Listed shows no prices and gives no investment advice.